Angiogenesis: A promising treatment option for peripheral arterial disease

Current Vascular Pharmacology

Volumn 6, Issue 2, 2008, Pages 78-80

  Paraskevas, Kosmas I ^a   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; VASCULOTROPIN; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR RISK; EDITORIAL; HEART FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PREDICTOR VARIABLE; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; TREATMENT RESPONSE; PHYSIOLOGY;

ANGIOGENESIS INDUCING AGENTS; ATHEROSCLEROSIS; FIBROBLAST GROWTH FACTORS; HUMANS; PERIPHERAL VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42049103336     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108783955356     Document Type: Editorial

References (43)

1. Steinberg BA, Ballantyne CM, Bhatt DL, Montalescot G, Mehta S, O'Hagan P, et al. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol 2007; 6: 72-75.
2. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007; 45: 1185-1191.
3. Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007; 58: 309-315.
4. Paraskevas KI, Mikhailidis DP, Liapis CD. Internal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors. Angiology 2007; 58: 329-335.
5. Barani J, Mattiasson I, Lindblad B, Gottsater A. Cardiac function, inflammatory mediators and mortality in critical limb ischemia. Angiology 2006; 57: 437-444.
6. Sonmez K, Eskisar AO, Demir D, Yazicioglu MV, Mutlu B, Dogan Y, et al. Increased urinary albumin excretion rates can be a marker of coexisting coronary artery disease in patients with peripheral arterial disease. Angiology 2007; 57: 15-20.
7. Hirch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease: detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
8. Doubeni CA, Yood RA, Emani S, Gurwitz JH. Identifying unrecognized peripheral arterial disease among asymptomatic patients in the primary care setting. Angiology 2006; 57: 171-180.
9. Khan S, Flather M, Mister R, Delahunty N, Fowkes G, Bradbury A, et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur J Vasc Endovasc Surg 2007; 33: 442-450.
10. Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, Liapis CD. Lipid management and peripheral arterial disease. Curr Drug Targets 2007; 8: 561-570.
11. Duprez DA. Pharmacological interventions for peripheral artery disease. Expert Opin Pharmacother 2007; 8: 1465-1477.
12. Rice TW, Lumsden AB. Optimal medical management of peripheral arterial disease. Vasc Endovascular Surg 2006; 40: 312-327.
13. Reiss AB, Edelman SD. Recent insights into the role of prostanoids in atherosclerotic vascular disease. Curr Vasc Pharmacol 2006; 4: 395-408.
14. Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 2006; 20: 696-705.
15. Kakafika AI, Mikhailidis DP. Smoking and aortic disease. Circ J 2007; 71: 1173-1180.
16. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007; 58: 450-457.
17. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol 2007; 5: 276-292.
18. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilatation in healthy young adults. Circulation 1993; 88: 2149-2155.
19. Giannini D, Leone A, Di Bisceglie D, Nuti M, Strata G, Buttitta F, et al. The effects of acute passive smoke exposure on endothelium-dependent brachial artery dilation in healthy individuals. Angiology 2007; 58: 211-217.
20. Achimastos AD, Efstathiou SP, Christoforatos T, Panagiotou TN, Stergiou GS, Mountokalakis TD. Arterial stiffness: determinants and relationship to the metabolic syndrome. Angiology 2007; 58: 11-20.
21. Fjeldstad AS, Fjeldstad C, Acree LS, Nickel KJ, Montgomery PS, Comp PC, et al. The relationship between arterial elasticity and metabolic syndrome features. Angiology 2007; 58: 5-10.
22. Oren S, Isakov I, Golzman B, Kogan J, Turkot S, Peled R, et al. The influence of smoking cessation on hemodynamics and arterial compliance. Angiology 2006; 57: 564-568.
23. Rojas A, Figueroa H, Morales MA, Re L. Facing up the ROS labyrinth- Where to go? Curr Vasc Pharmacol 2006; 4: 277-289.
24. Youssef F, Gupta P, Mikhailidis DP, Hamilton G. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 2005; 56: 279-287.
25. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62.
26. Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology 2006; 57: 65-71.
27. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007;23: 553-563.
28. Fatourou EM, Paraskevas KI, Seifalian AM, Hamilton G, Mikhailidis DP. The role of established and emerging risk factors in peripheral vascular graft occlusion. Expert Opin Pharmacother 2007; 8: 901-911.
29. Yacyshyn VJ, Thatipelli MR, Lennon RJ, Bailey KR, Stanson AW, Holmes DR Jr, et al. Predictors of failure of endovascular therapy for peripheral arterial disease. Angiology 2006; 57: 403-417.
30. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 Suppl 1: S1-75.
31. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-654.
32. Mikroulis D, Papanas N, Maltezos E, Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol 2007; 5: 195-209.
33. Jia L, Takahashi M, Yoshioka T, Morimoto H, Ise H, Ikeda U. Therapeutic potential of endothelial progenitor cells for cardiovascular diseases. Curr Vasc Pharmacol 2006; 4: 59-65.
34. Rohovsky S, Kearney M, Pieczek A, Rosenfield K, Schainfeld R, D'Amore PA, et al. Elevated levels of basic fibroblast growth factor in patients with limb ischemia. Am Heart J 1996; 132: 1015-1019.
35. Lin JW, Sheu WH, Lee WJ, Chen YT, Liu TJ, Ting CT, et al. Circulating hepatocyte growth factor level but not basic fibroblast growth factor level is elevated in angiography-proven symptomatic peripheral artery disease. Angiology 2007; 58: 420-428.
36. Arai Y, Fujita M, Marui A, Hirose K, Sakaguchi H, Ikeda T, et al. Combined treatment with sustained-release basic fibroblast growth factor and heparin enhances neovascularization in hypercholesterolemic mouse hindlimb ischemia. Circ J 2007; 71: 412-417.
37. Hirose K, Fujita M, Marui A, Arai Y, Sakaguchi H, Huang Y, et al. Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. Circ J 2006; 80: 1190-1194.
38. Doi K, Ikeda T, Marui A, Kushibiki T, Arai Y, Hirose K, et al. Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia. Heart Vessels 2007; 22: 104-108.
39. Ozawa T, Kato K, Sanada H, Makiyama Y, Saigawa T, Souda S, et al. Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia-a case report. Angiology 2006; 57: 235-239.
40. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435.
41. Koshikawa M, Shimodaira, Yoshioka T, Kasai H, Watanabe N, Wada Y, et al. Therapeutic angiogenesis by bone marrow implantation of critical hand limb ischemia in patients with peripheral arterial disease: a pilot study. Curr Med Res Opin 2006; 22: 793-798.
42. Higashi Y, Kimura M, Hara K, Noma K, Jitsuiki D, Nakagawa K, et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilatation in patients with limb ischemia. Circulation 2004; 109: 1215-1218.
43. Tse HF, Yiu KH, Lau CP. Bone marrow stem cell therapy for myocardial angiogenesis. Curr Vasc Pharmacol 2007; 5: 103-112.